Half a dozen agents stood out – for good and not so good reasons
Challenges and limitations associated with bispecific ADCs
A look at some novel targets and payloads worth looking at
The pace of early stage drug development in oncology is amazing
W2W4 in terms of rapidly evolving and dynamic niches in early stage development
A critique of the updated CytomX Varseta-M data
A number of different mechanisms are emerging to block KRAS in combination
A look at the evolving bladder cancer market and how changes affect what comes next
Strategic insights on the evolving prostate cancer landscape
"It was totally the wrong approach": a CSO on how the ADC field lost its way
The recent debate around trastuzumab deruxtecan (T-DXd) resistance has quietly split into two camps:…
Filling pipeline gaps is becoming more art than science
Why 'practice changing' data may not be all it's cracked up to be
Next generation approaches to watch out for are coming from the East
Review of 10 key early and late stage trials, including Relay and Scorpion's mutant selective PI3Kα inhibitors
“The future is not set. There is no fate but what we make for ourselves.” This quote…
The hunt for novel payloads for ADCs continues apace
A new approach to targeting tumour suppressors with a cancer therapeutic
Some protein degraders are finally looking promising while the next generation DACs may turn a few heads
A look at emerging ADCs in many shapes and flavours, including dual and novel payload versions
New developments in metastatic and early stage breast cancer from Berlin
Highlights and lowlights from Day 1 of ESMO25
Standing out from the crowd – 6 ADC trends to watch out for at ESMO
An engaging conversation with Dan Chen about ADCs and T cell engagers
Regardless of the rumourmill, there are some new ADC data to explore
For years prognosis in SCLC has remained dismal, now we have wealth of agents to watch out for
While all eyes are on chemo combos in EGFR mt NSCLC, a bispecific ADC may give them a run for their money
In an industry littered with discontinued programs and dashed hopes, Merck is placing some contrarian…
What's story – is an emerging niche dead on arrival or will success come from next gen agents?
A few years ago Five Prime tried blocking B7-H4 with a naked antibody called FPA150 and saw limited…
Ignore FDA advice at your peril!
Six of the best...
An emerging subniche in the ADC space
As the PD(L)1 x VEGF niche explodes, small differences in design could make an impact on performance
Does X mark the spot – or not?
Trials and tribulations associated with IO agents in solid tumours
Finding pearls before swine
Bridging the gaps in ADCs and TPD at AACR25
A look at the breast cancer data for 3 rising early stage compounds
A rapid evolving field creates challenges for those following the leaders since the SOC can change quickly
When resistance and toxicities collide, the inevitable fallout is more likely
What's looking interesting in early stage trials at ASCO24?
Some up and coming novel ADCs to watch out for
